MTOR and cancer: Treatment of ACHN cells with the NR4A1 antagonists DIM-C-pPhOH (Fig 6B) and DIM-C-pPhCO2Me (Fig 6C) also induced sestrin 2, activated AMPKα and inhibited activation of mTOR and downstream kinases and these results are consistent with previous studies in other cancer cells expressing wild-type p53 [15, 17].